Sign in to edit your profile (add interests, mentoring, photo, etc.)

    Mitchell E. Gross, MD, PhD

    TitleAssociate Professor of Clinical Medicine
    SchoolKeck School of Medicine of USC
    AddressCSC 240
    Health Sciences Campus
    Los Angeles California 90089-9075
    Phone+1 310 272 7640
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview
      Dr. Gross is research director of the USC Norris Westside Cancer Center and the Center for Applied Molecular Medicine. His overall research interest focuses on applying modern techniques relating to the study of genes and proteins (genomics and proteomics) on the clinical problems faced in treating patients with prostate cancer. A particular interest relates to the androgen receptor and relating proteins and pathways as key driving forces behind the development and treatment of prostate cancer. As a medical oncologist, his clinical activities are focused on therapeutic clinical trials incorporating both molecularly targeted and conventional therapies to the care of patients with prostate cancer. He serves as primary investigator on many multi-center phase 1 and 2 clinical trials

      Dr. Gross has earned degrees from the University of California, San Diego (B.A.), Baylor College of Medicine in Houston (M.D.), and the University of California, Los Angeles (Ph.D. Molecular Biology). He completed a residency in internal medicine and a fellowship in hematology and medical oncology at the UCLA Center for the Health Sciences.

      Collapse Biography 
      Collapse Clinical Trials
      Collapse Awards and Honors
      1989Phi Beta Kappa
      UCSD/Revelle College Academic1990Leadership Award
      1994Alpha Omega Alpha
      1994Hewlett Packard Award for Excellence in Internal Medicine
      1997  - 2002Specialty Training Advanced Research Fellowship
      1999Amgen Fellowship Research Award
      1999Rhone Phoulenc Rorer Travel Award
      2001AACR-AFLAC Scholar in Training Award,
      2006Donna and Jesse Garber Award

      Collapse ORNG Applications 
      Collapse Websites

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Gross M, Dorff TB, Quinn DI, Diaz PM, Castellanos OO, Agus DB. Safety and Efficacy of Docetaxel, Bevacizumab, and Everolimus for Castration-resistant Prostate Cancer (CRPC). Clin Genitourin Cancer. 2017 Jul 14. PMID: 28826933.
        View in: PubMed
      2. Kiwata JL, Dorff TB, Todd Schroeder E, Salem GJ, Lane CJ, Rice JC, Gross M, Dieli-Conwright CM. A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy. BMJ Open. 2017 Jul 10; 7(7):e016910. PMID: 28698349.
        View in: PubMed
      3. Tennill TA, Gross M, Frieboes HB. Automated analysis of co-localized protein expression in histologic sections of prostate cancer. PLoS One. 2017; 12(5):e0178362. PMID: 28552967.
        View in: PubMed
      4. Liao CP, Chen LY, Luethy A, Kim Y, Kani K, MacLeod AR, Gross M. Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells. Endocr Relat Cancer. 2017 Apr; 24(4):157-170. PMID: 28264911.
        View in: PubMed
      5. Gross M. Blood-based gene expression profiling in castrate-resistant prostate cancer. BMC Med. 2015 Sep 14; 13:219. PMID: 26365516; PMCID: PMC4568585.
      6. van den Bos W, Muller BG, de Bruin DM, de Castro Abreu AL, Chaussy C, Coleman JA, Finelli A, Gill IS, Gross M, Jenniskens SF, Kahmann F, Laguna-Pes MP, Rastinehad AR, Simmons LA, Sulser T, Villers A, Ward JF, de la Rosette JJ. Salvage ablative therapy in prostate cancer: international multidisciplinary consensus on trial design. Urol Oncol. 2015 Nov; 33(11):495.e1-7. PMID: 26231310.
        View in: PubMed
      7. Patel N, Itakura T, Jeong S, Liao CP, Roy-Burman P, Zandi E, Groshen S, Pinski J, Coetzee GA, Gross M, Fini ME. Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression. PLoS One. 2015; 10(2):e0117758. PMID: 25693195; PMCID: PMC4333349.
      8. Ukimura O, Gross M, de Castro Abreu AL, Azhar RA, Matsugasumi T, Ushijima S, Kanazawa M, Aron M, Gill IS. A novel technique using three-dimensionally documented biopsy mapping allows precise re-visiting of prostate cancer foci with serial surveillance of cell cycle progression gene panel. Prostate. 2015 Jun; 75(8):863-71. PMID: 25663102.
        View in: PubMed
      9. Ukimura O, Marien A, Palmer S, Villers A, Aron M, de Castro Abreu AL, Leslie S, Shoji S, Matsugasumi T, Gross M, Dasgupta P, Gill IS. Trans-rectal ultrasound visibility of prostate lesions identified by magnetic resonance imaging increases accuracy of image-fusion targeted biopsies. World J Urol. 2015 Nov; 33(11):1669-76. PMID: 25656687.
        View in: PubMed
      10. Dorff TB, Gross M. Radium 223: how can we optimize this new tool for metastatic castration-resistant prostate cancer? Am Soc Clin Oncol Educ Book. 2015; e270-3. PMID: 25993185.
        View in: PubMed
      11. Dorff TB, Groshen S, Tsao-Wei DD, Xiong S, Gross M, Vogelzang N, Quinn DI, Pinski JK. A Phase II trial of a combination herbal supplement for men with biochemically recurrent prostate cancer. Prostate Cancer Prostatic Dis. 2014 Dec; 17(4):359-65. PMID: 25245366; PMCID: PMC4234307.
      12. Dago AE, Stepansky A, Carlsson A, Luttgen M, Kendall J, Baslan T, Kolatkar A, Wigler M, Bethel K, Gross M, Hicks J, Kuhn P. Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells. PLoS One. 2014; 9(8):e101777. PMID: 25084170; PMCID: PMC4118839.
      13. Eisenberg SA, Kurita K, Taylor-Ford M, Agus DB, Gross M, Meyerowitz BE. Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors. Psychooncology. 2015 Feb; 24(2):228-35. PMID: 24891013.
        View in: PubMed
      14. Dreicer R, MacLean D, Suri A, Stadler WM, Shevrin D, Hart L, MacVicar GR, Hamid O, Hainsworth J, Gross M, Shi Y, Webb IJ, Agus DB. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2014 Mar 01; 20(5):1335-44. PMID: 24418642.
        View in: PubMed
      15. Gross M. Prostate cancer: Age is nothing but a number. Nat Rev Urol. 2013 12; 10(12):683-4. PMID: 24217679.
        View in: PubMed
      16. Kani K, Malihi PD, Jiang Y, Wang H, Wang Y, Ruderman DL, Agus DB, Mallick P, Gross M. Anterior gradient 2 (AGR2): blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype. Prostate. 2013 Feb 15; 73(3):306-15. PMID: 22911164.
        View in: PubMed
      17. Jadvar H, Desai B, Ji L, Conti PS, Dorff TB, Groshen SG, Gross M, Pinski JK, Quinn DI. Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer. Clin Nucl Med. 2012 Jul; 37(7):637-43. PMID: 22691503; PMCID: PMC3375600.
      18. Amato RJ, Wilding G, Bubley G, Loewy J, Haluska F, Gross M. Safety and preliminary efficacy analysis of the mTOR inhibitor ridaforolimus in patients with taxane-treated, castration-resistant prostate cancer. Clin Genitourin Cancer. 2012 Dec; 10(4):232-8. PMID: 22695254; PMCID: PMC3963491.
      19. Desai B, Gross M, Jadvar H. Multimodality imaging in biochemical recurrence of prostate cancer: utility of (18)F-NaF PET/CT in early detection of metastasis. Rev Esp Med Nucl Imagen Mol. 2012 Jul-Aug; 31(4):231-2. PMID: 22980132; PMCID: PMC3458514.
      20. Bahn D, de Castro Abreu AL, Gill IS, Hung AJ, Silverman P, Gross M, Lieskovsky G, Ukimura O. Focal cryotherapy for clinically unilateral, low-intermediate risk prostate cancer in 73 men with a median follow-up of 3.7 years. Eur Urol. 2012 Jul; 62(1):55-63. PMID: 22445223.
        View in: PubMed
      21. Taylor-Ford M, Meyerowitz BE, D'Orazio LM, Christie KM, Gross M, Agus DB. Body image predicts quality of life in men with prostate cancer. Psychooncology. 2013 Apr; 22(4):756-61. PMID: 22422671.
        View in: PubMed
      22. Kani K, Faca VM, Hughes LD, Zhang W, Fang Q, Shahbaba B, Luethy R, Erde J, Schmidt J, Pitteri SJ, Zhang Q, Katz JE, Gross M, Plevritis SK, McIntosh MW, Jain A, Hanash S, Agus DB, Mallick P. Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition. Mol Cancer Ther. 2012 May; 11(5):1071-81. PMID: 22411897; PMCID: PMC3959865.
      23. Lazar DC, Cho EH, Luttgen MS, Metzner TJ, Uson ML, Torrey M, Gross M, Kuhn P. Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Phys Biol. 2012 Feb; 9(1):016002. PMID: 22306736; PMCID: PMC3387997.
      24. Ukimura O, Desai MM, Palmer S, Valencerina S, Gross M, Abreu AL, Aron M, Gill IS. 3-Dimensional elastic registration system of prostate biopsy location by real-time 3-dimensional transrectal ultrasound guidance with magnetic resonance/transrectal ultrasound image fusion. J Urol. 2012 Mar; 187(3):1080-6. PMID: 22266005.
        View in: PubMed
      25. Gross M, Leichman L, Lowe ES, Swaisland A, Agus DB. Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemother Pharmacol. 2012 Jan; 69(1):273-80. PMID: 22002543.
        View in: PubMed
      26. Dorff TB, Gross M. The epothilones: new therapeutic agents for castration-resistant prostate cancer. Oncologist. 2011; 16(10):1349-58. PMID: 21964003; PMCID: PMC3228074.
      27. Yu EY, Massard C, Gross M, Carducci MA, Culine S, Hudes G, Posadas EM, Sternberg CN, Wilding G, Trudel GC, Paliwal P, Fizazi K. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology. 2011 May; 77(5):1166-71. PMID: 21539969; PMCID: PMC3394099.
      28. Quinn D, Gross M. Show us a sign: the search for "game changing" prostate cancer biomarkers. Lancet Oncol. 2011 Mar; 12(3):204-6. PMID: 21310657.
        View in: PubMed
      29. Mink SR, Hodge A, Agus DB, Jain A, Gross M. Beta-2-microglobulin expression correlates with high-grade prostate cancer and specific defects in androgen signaling. Prostate. 2010 Aug; 70(11):1201-10. PMID: 20564426.
        View in: PubMed
      30. Jiang Y, Palma JF, Agus DB, Wang Y, Gross M. Detection of androgen receptor mutations in circulating tumor cells in castration-resistant prostate cancer. Clin Chem. 2010 Sep; 56(9):1492-5. PMID: 20581083.
        View in: PubMed
      31. Bradley DA, Daignault S, Ryan CJ, Dipaola RS, Cooney KA, Smith DC, Small E, Mathew P, Gross M, Stein MN, Chen A, Pienta KJ, Escara-Wilke J, Doyle G, Al-Hawary M, Keller ET, Hussain M. Cilengitide (EMD 121974, NSC 707544) in asymptomatic metastatic castration resistant prostate cancer patients: a randomized phase II trial by the prostate cancer clinical trials consortium. Invest New Drugs. 2011 Dec; 29(6):1432-40. PMID: 20336348; PMCID: PMC2917503.
      32. Christie KM, Meyerowitz BE, Giedzinska-Simons A, Gross M, Agus DB. Predictors of affect following treatment decision-making for prostate cancer: conversations, cognitive processing, and coping. Psychooncology. 2009 May; 18(5):508-14. PMID: 18756584.
        View in: PubMed
      33. Müller CI, Miller CW, Hofmann WK, Gross M, Walsh CS, Kawamata N, Luong QT, Koeffler HP. Rare mutations of the PIK3CA gene in malignancies of the hematopoietic system as well as endometrium, ovary, prostate and osteosarcomas, and discovery of a PIK3CA pseudogene. Leuk Res. 2007 Jan; 31(1):27-32. PMID: 16764926.
        View in: PubMed
      34. Shazer RL, Luthringer D, Agus DB, Gross M. Ductal adenocarcinoma of the prostate. Clin Adv Hematol Oncol. 2004 Jun; 2(6):393-5; discussion 396. PMID: 16163211.
        View in: PubMed
      35. Gross M, Shazer RL, Agus DB. Targeting the HER-kinase axis in cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):9-20. PMID: 15052539.
        View in: PubMed
      36. Gross M, Jo S, Agus DB. Update on HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol Oncol. 2004 Jan; 2(1):53-6, 64. PMID: 16163160.
        View in: PubMed